GATC Health Paper Quantifies AI-Driven Capital Efficiencies and Advances Human-Centered Drug Discovery

IRVINE, Calif., May 22, 2025 /PRNewswire/ -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has published a new paper, AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine. The paper details how advancements such as GATC's Multiomics Advanced Technology^™ (MAT) platform are reshaping pharmaceutical development by improving speed, cost, and accuracy while reducing reliance on animal testing through human-relevant AI models. Ultimately, these technologies provide practical solutions to the industry's key challenges and promise to deliver better, safer treatments—faster—to patients.

Highlights include:

• Validated, Highly Accurate Predictions: GATC Health's MAT was validated by University of California, Irvine, with predictions of sensitivity at 86% and specificity at 91%.
• Digital Twin Models: Models of human biological systems can test thousands of drug candidates in silico—achieving results 1,000x faster than conventional methods and at dramatically lower cost.
• Reduction in Animal Testing: The platform simulates human biology, enabling accurate predictions without animal studies and supporting regulatory shifts like the FDA Modernization Act. AI-driven methods could replace animal testing for up to 38.4 million animals annually.
• Public Health Impact: Accelerated drug development means faster access to new therapeutics, with the potential to save millions of years of human life.

"This paper underscores our commitment to scientific and ethical progress in drug discovery," said Jayson Uffens, Chief Technology Officer at GATC Health. "By improving capital efficiency and reducing animal testing, we aim to advance both innovation and responsibility in the industry."

Transforming Drug Development Economics
Traditional drug development can cost up to $2.4 billion and take 12 years per drug. GATC's MAT platform streamlines discovery and preclinical phases, enabling companies to avoid costly investments in unlikely candidates and reinvest savings into further research. As noted in the paper, AI-driven preclinical assessments can cut animal use, increase human relevance, and reduce expenses by up to 90%. This streamlined process can shorten time to Investigational New Drug (IND) filing from over a decade to under two years.

Advancing Ethical, Cost-Effective Solutions
Conventional animal models often fail to predict human outcomes and raise ethical issues. GATC's AI-driven approach reduces animal use by up to 70% per drug candidate, aligning with global moves toward non-animal testing. Virtual toxicology datasets and digital twins replace animal models with more accurate and humane alternatives.

Aligning with Regulatory Trends
The paper details how AI technologies support evolving regulatory requirements, enabling faster, more precise, and ethically responsible drug development. GATC Health invites industry stakeholders to review the full paper and participate in the ongoing dialogue about the future of drug discovery. Visit GATC Health's Resources page to download the full paper.

About GATC Health
GATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company's validated and proprietary Multiomics Advanced Technology^™ (MAT) simulates human biochemistry's billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and derisk drug pipelines by predicting efficacy, safety, and off-target effects.
For more information, visit www.gatchealth.com.

SOURCE GATC Health Corp